Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sci PharmtechTPE:4119 78 3-1 Month Momentum % is 17.36% as of Sep. 05, 2026. GuruFocus rates TPE:4119 with a GF Score™ of 78/100 and a GF Value™ of NT$74.57 (Modestly Undervalued). The stock has 11 warning signs investors should review. Among 1,022 Drug Manufacturers companies, Sci Pharmtech ranks better than 88.94% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-05), Sci Pharmtech's 3-1 Month Momentum % is 17.36%.
The industry rank for Sci Pharmtech's 3-1 Month Momentum % or its related term are showing as below:
TPE:4119's 3-1 Month Momentum % is ranked better than 88.94% of 1022
companies
in the Drug Manufacturers industry
Industry Median: -1.16
vs TPE:4119: 17.36
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Sci Pharmtech 3-1 Month Momentum % Related Terms
TPE:4119 vs ZTS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sci Pharmtech's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sci Pharmtech 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sci Pharmtech's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Sci Pharmtech's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sci Pharmtech (TPE:4119) has a 3-1 Month Momentum % of 17.36% as of Sep. 05, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Sci Pharmtech and its competitors. According to the industry distribution chart, Sci Pharmtech ranks #113 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 11.1%.
Is Sci Pharmtech's 3-1 Month Momentum % too high?
Sci Pharmtech's current 3-1 Month Momentum % is 17.36%. Based on the distribution chart, Sci Pharmtech ranks #113 out of 1022 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sci Pharmtech has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sci Pharmtech's 3-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sci Pharmtech ranks #113 out of 1022 companies for 3-1 Month Momentum %. This places Sci Pharmtech in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Sci Pharmtech and its competitors. Sci Pharmtech's current 3-1 Month Momentum % is 17.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sci Pharmtech stock overvalued right now?
Based on GuruFocus' analysis, Sci Pharmtech (TPE:4119) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$74.57, compared to a current price of NT$56.10 — trading 24.8% below its estimated fair value. The current 3-1 Month Momentum % is 17.36%. Sci Pharmtech's overall GF Score™ is 78/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Sci Pharmtech (TPE:4119), the current 3-1 Month Momentum % is 17.36% as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sci Pharmtech (TPE:4119) Overvalued in 2026?
Based on GuruFocus' analysis, Sci Pharmtech stock appears to be undervalued.
The current stock price of NT$56.10 is trading 24.8% below its estimated GF Value™ of NT$74.57.
GuruFocus considers Sci Pharmtech to be Modestly Undervalued.
Key valuation signals for TPE:4119:
3-1 Month Momentum %: 17.36%
GF Value™: NT$74.57 vs. price of NT$56.10 (24.8% below fair value)
No single metric tells the full story. See the TPE:4119 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sci Pharmtech Inc is engaged in the research and development, manufacture, and sales of active pharmaceutical ingredients, intermediates, and specialty chemicals. Geographically, the primary markets of the company are Italy, Germany, Japan, Taiwan, the United States, Switzerland, Spain, Belgium, Netherlands, and others.
78GF Score
Get the complete analysis for TPE:4119
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4119 has been successfully added to your 
